JP5156330B2 - Adipose tissue weight reducing agent - Google Patents

Description

The present invention relates to an adipose tissue weight reducing agent for the purpose of preventing obesity, and more particularly to an adipose tissue weight reducing agent containing a collagen peptide as an active ingredient and ingested in combination with exercise load .

  Accumulation of visceral fat and lack of exercise due to excessive intake of fat cause various lifestyle-related diseases. The main lifestyle-related diseases resulting from visceral fat accumulation and lack of exercise include obesity, diabetes, arteriosclerosis, and hyperlipidemia, which can significantly impair health. Several ingredients such as green tea extract and amino acid mixture are known for promoting lipid metabolism, reducing visceral fat, and preventing and improving these lifestyle-related diseases. High materials are required.

  On the other hand, collagen is the most abundant protein in mammals and is the main fibrous element of skin, bones, tendons, cartilage, blood vessels, and teeth. Collagen has been ingested for a long time, and effects such as alleviation of symptoms of osteoarthritis (see Non-Patent Document 1) and cosmetic effects (see Non-Patent Document 2) have been reported.

In addition, a lipid metabolism improving agent in which microbial-derived hydroxyproline and its derivatives, which are the main amino acids of collagen, improve hypertriglyceridemia and high free fatty acidemia has been reported (Patent Document 1). Furthermore, an anti-obesity composition comprising a protein and water-soluble dietary fiber and / or gelatin and a basic amino acid and / or basic peptide has been reported (Patent Document 2). Here, collagen and collagen hydrolyzate are described as proteins, and basic peptides having a molecular weight of about 500 to 4000 are exemplified. Further, a test example in which collagen protein (average molecular weight 20000), gelatin and a basic peptide (average molecular weight 1800) are added to improve gel strength, a commercial feed, soy protein (average molecular weight 50000), carrageenan and arginine rat An example of an anti-obesity test using is described. Furthermore, a composition comprising 80% collagen hydrolyzate, 10% gelatin, basic peptide (molecular weight 1800) and 3% potassium chloride is described as an example. It is described that a mixed composition composed of protein, water-soluble dietary fiber, basic amino acids, etc. improves gel strength and stabilizes the gel state in the stomach, thereby suppressing digestion and absorption and preventing obesity. . Furthermore, it has been reported that gelatin showed an effect of improving serum triglyceride and cholesterol in a test using rats (Non-patent Document 3). However, none of these documents has sufficiently studied the anti-obesity activity and lipid metabolism improving activity of the collagen peptide itself. In addition, since the forms and causes of obesity are diverse and there are large individual differences in response to drugs, new, safe and effective anti-obesity agents are constantly being sought, and the forms and causes of abnormal lipid metabolism are also diverse. Due to the large individual differences in drugs, new, safe and effective metabolic improvers are constantly being sought.
Biomed Pharmacother, Vol. 50, p. 24-28, 1996 Cosmet Toiletries, Vol. 103, p. 77-80, 1988 Nutriton Research, Vol. 22, no. 3, p. 297-311, 2002 Republished Patent No. WO2004 / 085389 Japanese Unexamined Patent Publication No. 2000-1440

An object of the present invention is to provide an adipose tissue weight reducing agent for the purpose of preventing obesity, and in particular, to provide an adipose tissue weight reducing agent containing a collagen peptide as an active ingredient and ingested in combination with exercise load. .

As a result of intensive studies to solve the above problems, it has been found that collagen peptides have a remarkable anti-obesity effect. Moreover, it discovered that the obesity prevention effect increased notably by using it in an exercise load state. That is, the present invention mainly has the following configuration.
(1) A fat tissue weight reducing agent comprising a collagen peptide as an active ingredient and ingested in combination with exercise load .

According to the present invention, it is possible to provide an adipose tissue weight reducing agent characterized in that it contains a collagen peptide as an active ingredient and is ingested in combination with exercise load, without further combining with other active ingredients, etc. , which Ri by the orally ingested like, especially visceral fat accumulation with weight loss effect can be significantly suppressed, excellent anti-obesity effect of facilitating safe and effective also affect lipid metabolism are obtained.

  The present invention is described in detail below.

  The collagen peptide according to the present invention may be a commercially available product or a product obtained by decomposing and lowering the molecular weight by enzymatic treatment using collagen extracted by heating animal bones and skins. Collagen peptide is a low-molecular-weight collagen, and it reacts with acidic polysaccharides and tannins used in foods and drinks, etc. compared to non-low-molecular collagen and gelatin that has been heated and denatured. It is difficult to cause precipitation and cloudiness, and can be ingested in large amounts without causing gelation when dissolved in water before use. The collagen peptide is obtained by hydrolyzing gelatin with an enzyme or an acid, and in the present invention, any molecular weight including commercially available products can be used. Particularly, collagen having an average molecular weight of about 500 to 20000 derived from pigs. Peptides are preferred. More preferably, it is a collagen peptide having an average molecular weight in the range of 1000 to 10,000.

  In order to produce the anti-obesity agent according to the present invention, the collagen peptide produced by the above method can be used, and can be formulated in combination with a known non-toxic pharmaceutical carrier in accordance with a conventional method. The anti-obesity agent according to the present invention can be administered in various dosage forms. For example, oral administration agents include solid agents such as tablets, granules, powders, capsules, and soft capsules, solutions, and suspensions. And liquids such as emulsifiers and emulsifiers, freeze-dried agents, and the like. These preparations can be prepared by conventional means in preparation. Examples of the non-toxic pharmaceutical carrier include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, albumin, water, Examples thereof include physiological saline. In addition, conventional additives such as stabilizers, lubricants, wetting agents, emulsifiers, binders and the like can be appropriately added as necessary. In the anti-obesity agent according to the present invention, the dosage of the anti-obesity agent component is appropriately selected and determined according to the patient's age, weight, symptoms, degree of disease, administration schedule, formulation form, etc. The dosage is about 0.01 to 2 g / kg body weight, and may be administered in several divided doses a day. A more preferable dose range is about 0.05 to 0.5 g / kg body weight per day.

  In addition, since the collagen peptide has not been reported to be toxic, it can be taken as a food or drink for the purpose of preventing obesity. The collagen peptide can be positioned as a food for specified health use, a nutritional functional food, a health food, or the like. As a functional food, for example, after adding a suitable auxiliary agent to a collagen peptide, using a conventional means, a state suitable for food, for example, granular, granular, tablet, capsule, soft capsule, paste What was formed in etc. can be used. This food and drink may be used for food as it is, and added to various foods (for example, ham, sausage, kamaboko, chikuwa, bread, butter, milk powder, confectionery, etc.), water, alcoholic beverages, fruit juice, You may add and use for drinks, such as milk and a soft drink. The amount of the collagen peptide to be blended with these foods and drinks is not particularly limited, but preferably 1 to 95% by weight is preferable for expecting the effect. The intake amount of the collagen peptide of the present invention in the form of such food is appropriately selected and determined according to age, body weight, symptom, degree of disease, form of food, etc. For example, 0.01 to 2 g / kg body weight per day The dosage may be divided into several times a day. A more preferable dose range is about 0.05 to 0.5 g / kg body weight per day.

  Furthermore, when ingesting an obesity-preventing agent and a food or drink containing the same according to the present invention, the obesity effect is remarkably increased when ingested in an exercise load. That is, when the intake of an anti-obesity agent and its food and drink and exercise load are combined, a weight reduction effect is markedly shown and a visceral fat tissue weight reduction effect is markedly shown. In this case, the exercise intensity is a light load, for example, a weight of 4% of the body weight is loaded and a few tens of minutes of swimming exercise is performed.

  Examples are given below to describe the present invention in more detail, but the present invention is not limited by these.

Experiments were conducted on weight loss effect of collagen peptide for the conditions shown in the following weight loss effect of collagen peptide oral administration and exercise.

(sample)
A powder of collagen peptide average molecular weight 5000 (molecular weight distribution 500-20000) derived from pig skin was used.

(Animal used)
Four-week-old male ddY mice (n = 10) were preliminarily raised for 1 week with food and water ad libitum.

(Sample administration method)
After one week of preliminary breeding, the animals were divided into 6 groups as follows.
Control group Collagen peptide 1083 mg / kg administration group Collagen peptide 2166 mg / kg administration group Exercise load control group Exercise load + collagen peptide 1083 mg / kg administration group Exercise load + collagen peptide 2166 mg / kg administration group

  Here, the collagen peptide administration group was prepared by dissolving 1083 mg / kg and 2166 mg / kg of collagen peptide in 0.3 ml of distilled water, respectively, and administered by oral gavage once a day for 5 days a week. To the control group and the exercise load control group, 0.3 ml of distilled water was orally administered.

(Exercise load method)
For the exercise load of the mouse, a swimming exercise in which a weight of 4% of the body weight was applied to the tail was used. The swimming exercise for the first week was divided into 15 minutes, 30 minutes, and 45 minutes, and after the second week, the swimming exercise for 45 minutes was performed 3 times a week for 5 weeks for a total of 6 weeks. A swimming tank having a length of 24 cm, a width of 15 cm, and a height of 15 cm was used, and the swimming depth was 20 cm and the water temperature was 28 ± 2 ° C.

  The body weight was measured every week for the above 6 groups of mice raised under the above conditions, and the measurement results up to 6 weeks are shown in FIG. The numerical value is an average value ± standard error (g / g body weight), and the reference numerals indicating the above six groups are shown in parentheses. Moreover, * and ** in the figure indicate significant differences from the collagen peptide administration group to the control group (student T-TEST), * indicates p <0.05, and ** indicates p <0.01. Furthermore, # in the figure indicates a significant difference between the collagen peptide administration group and the exercise load control group, and # indicates p <0.05.

  From FIG. 1, the weight of the exercise load + collagen peptide 2166 mg / kg administration group was significantly lower than the control group and the exercise load control group in the second week, and the control group was significantly lower in the fifth week. Indicated. From this, it was shown that the collagen peptide has a weight loss effect, and it has been shown that the effect is remarkably increased by taking the exercise load and the collagen peptide in combination. In addition, the effect of the collagen peptide 2166 mg / kg administration group was more clearly shown than that of the collagen peptide 1083 mg / kg.

Effect of reducing the weight of peritesticular adipose tissue by oral administration of collagen peptide and exercise load Mice were bred under the same conditions as in Example 1, and the peritesticular adipose tissue weight was measured in each group dissected 6 weeks later. The result is shown in FIG. Numerical values are mean values ± standard error (g / g body weight). In the figure, *** indicates a significant difference between the collagen peptide administration group and the control group (student's T-TEST), and *** indicates p < Represents 0.005. In the figure, # indicates a significant difference between the collagen peptide administration group and the exercise load control group, and # indicates p <0.005. The measured values shown in FIG. 2 are shown in Table 1 below.

  From FIG. 2 and Table 1, the collagen peptide-administered group tends to show a lower value of the peritesticular adipose tissue weight than the control group. In particular, the exercise load + collagen peptide 2166 mg / kg administration group has the control group and the exercise load. The weight around the testis was significantly lower than that of the control group. This indicates that the collagen peptide has an effect of reducing the weight of the testicular adipose tissue, that is, has an effect of suppressing the accumulation of fat in the body, and the effect is more remarkable by taking a combination of exercise load and collagen peptide. It was shown to increase.

Effect of reducing collagen free fatty acid concentration by oral administration of collagen peptide and exercise load Mice were bred under the same conditions as in Example 1, and the plasma free fatty acid concentration in each group was measured 6 weeks later. The result is shown in FIG. The numerical value is an average value ± standard error (mEq / l). In the figure, * indicates a significant difference between the collagen peptide administration group and the control group (student's T-TEST), and represents p <0.05. The measured values shown in FIG. 3 are shown in Table 2 below.

  From FIG. 3 and Table 2, the exercise load + collagen peptide 2166 mg / kg administration group showed significantly lower plasma free fatty acid concentration than the control group. From this, it was shown that ingesting a combination of exercise load and collagen peptide affects not only obesity prevention effects but also lipid metabolism.

According to the present invention, it is possible to provide an adipose tissue weight-reducing agent containing a collagen peptide as an active ingredient and ingested in combination with exercise load, and a new use of a collagen peptide is provided. is, for good Ri excellent anti-obesity effect and fat metabolism promoting effect is obtained, it is extremely useful.

It is a figure which shows the weight change by exercise load and collagen peptide administration. It is a figure which shows the change of the testicular fat tissue weight by exercise load and collagen peptide administration. It is a figure which shows the change of the plasma free fatty acid concentration by exercise load and collagen peptide administration.

Claims (5)

A fat tissue weight reducing agent comprising a collagen peptide as an active ingredient and ingested in combination with exercise load . 2. The adipose tissue weight reducing agent according to claim 1, which is a porcine collagen peptide. The adipose tissue weight reducing agent according to claim 1 or 2, which is a collagen peptide having an average molecular weight of 500 to 20,000. The fat tissue weight reducing agent according to any one of claims 1 to 3, wherein the fat tissue weight reducing agent is taken by oral administration. The adipose tissue weight reducing agent according to any one of claims 1 to 4, wherein a daily dose is 0.01 to 2 g / kg body weight .

Images